000756 新华制药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入4,732,4811.29%8,100,8457,502,9876,560,0786,005,587
减:营业总成本4,414,1942.38%7,530,9057,020,4786,173,7365,585,070
    其中:营业成本3,547,9328.13%5,709,1425,465,6564,786,4104,190,990
               财务费用1,61820.56%16,35132,01952,90383,710
               资产减值损失(48,314)8.96%(69,283)(43,526)(33,267)(45,159)
公允价值变动收益------------
投资收益9,51714.85%9,5838,3658,0175,611
    其中:对联营企业和合营企业的投资收益1,3341,006.56%1,418447(1,089)(2,978)
营业利润307,570-7.90%534,582476,707425,591422,485
利润总额303,364-8.61%532,686471,774421,233411,638
减:所得税费用30,597-45.62%26,57945,66559,15964,525
净利润272,766-1.06%506,107426,110362,074347,113
减:非控股权益7,36225.35%9,59515,04713,52622,254
股东净利润265,404-1.63%496,512411,063348,548324,860

市场价值指针
每股收益 (元) *0.390-2.50%0.7400.6200.5600.520
每股派息 (元) *0.025--0.2500.2000.1500.150
每股净资产 (元) *6.9678.51%6.7496.1625.5285.184
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容